Drug Profile
VLA 84
Alternative Names: Clostridium difficile vaccine - Valneva/GlaxoSmithKline; Clostridium difficile vaccine - Valneva/Novartis; IC-84; VLA84Latest Information Update: 28 Mar 2019
Price :
$50
*
At a glance
- Originator Intercell
- Developer Valneva
- Class Bacterial vaccines; Protein vaccines; Recombinant fusion proteins; Recombinant proteins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Clostridium difficile infections
Highest Development Phases
- Phase II Clostridium difficile infections
Most Recent Events
- 28 Mar 2019 No recent reports of development identified for phase-I development in Clostridium-difficile-infections(Prevention, In volunteers) in Austria (IM, Injection)
- 28 Mar 2019 No recent reports of development identified for phase-I development in Clostridium-difficile-infections(Prevention, In volunteers) in Hungary (IM, Injection)
- 12 Apr 2017 Immunogenicity and safety data from a phase II study in Clostridium difficile infections presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2017)